Jasper Therapeutics Q2 2024 GAAP EPS $(0.97) Beats $(1.08) Estimate; Cash $106.8M
Portfolio Pulse from Benzinga Newsdesk
Jasper Therapeutics (NASDAQ:JSPR) reported a Q2 2024 GAAP EPS of $(0.97), beating the analyst estimate of $(1.08) by 10.19%. This represents a 34.01% improvement over the same period last year. The company has $106.8M in cash.
August 13, 2024 | 11:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jasper Therapeutics reported a Q2 2024 GAAP EPS of $(0.97), beating estimates and showing significant improvement YoY. The company also has strong cash reserves of $106.8M.
The better-than-expected EPS and significant YoY improvement are positive indicators for investors. The strong cash reserves further bolster the company's financial stability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100